Apogee Therapeutics CMO Dambkowski Carl Sells 2725 Shares at $37.82-$38.55/Share.

Apogee Therapeutics, Inc. [APGE] has announced that Chief Medical Officer Dambkowski Carl has engaged in two separate transactions involving the sale of shares. Firstly, Mr. Dambkowski Carl sold 2,535 shares at a price of $37.82 per share on September 3, 2025. Secondly, he sold an additional 190 shares at a price of $38.55 per share on the same date.

Apogee Therapeutics Inc. [APGE] has reported that its Chief Medical Officer, Carl Dambkowski, has engaged in two separate transactions involving the sale of shares. The first transaction saw Mr. Dambkowski sell 2,535 shares at a price of $37.82 per share on September 3, 2025. In a subsequent transaction on the same date, he sold an additional 190 shares at a price of $38.55 per share [1].

These transactions come as Apogee Therapeutics continues to face financial challenges. The company reported a loss of $1.13 per share for the last quarter, falling short of analyst estimates. Analysts forecast an EPS of -3.09 for the current fiscal year [1].

Insiders own 42.77% of the company's stock, including Mr. Dambkowski, who now owns 236,273 shares after these transactions [1]. Despite the recent insider sales, institutional investors and hedge funds now hold 79.04% of the company's stock, reflecting a growing interest in the biotechnology sector [1].

Apogee Therapeutics is set to participate in the Stifel 2025 Virtual Immunology and Inflammation Forum, where members of management will engage in a fireside chat on September 16, 2025 [2]. The company is advancing novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications [2].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-apogee-therapeutics-inc-apge-shares-bought-by-allostery-investments-lp-2025-09-03/
[2] https://www.biospace.com/press-releases/apogee-therapeutics-to-participate-at-the-stifel-2025-virtual-immunology-and-inflammation-forum